Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Edaravone→

Edaravone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
89-25-8
PubChem CID
4021
Molecular formula
C10H10N2O
Molecular weight
174.20 g/mol
Drug class
Free-radical scavengerantioxidant neuroprotective small molecule
Mechanism of action
The mechanism by which edaravone produces clinical benefit in amyotrophic lateral sclerosis (ALS) is not fully understood. It scavenges free radicals and may reduce oxidative stress and lipid peroxidation; these effects should not be equated with a proven disease-modifying molecular pathway.
Indications / reported uses
  • Treatment of amyotrophic lateral sclerosis (ALS) in adults under the US product indication; the clinical benefit is described as slowing decline in physical function in the studied population

Sources: US DailyMed — RADICAVA / RADICAVA ORS (edaravone) · US FDA prescribing information · FDA product information

Identification source: PubChem record (CID 4021). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Free-radical scavenger; antioxidant neuroprotective small molecule

Mechanism of action

The mechanism by which edaravone produces clinical benefit in amyotrophic lateral sclerosis (ALS) is not fully understood. It scavenges free radicals and may reduce oxidative stress and lipid peroxidation; these effects should not be equated with a proven disease-modifying molecular pathway.

General use cases

  • Treatment of amyotrophic lateral sclerosis (ALS) in adults under the US product indication; the clinical benefit is described as slowing decline in physical function in the studied population

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Edaravone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Edaravone Permitted Daily Exposure (PDE) report (the Edaravone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Edaravone Occupational Exposure Limit (OEL) report (the Edaravone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.